- New data on Incyte’s (NASDAQ:INCY) Zynyz (retifanlimab) showed that the monoclonal antibody added to standard chemotherapy led to improved progession-free survival than chemo alone in squamous cell anal carcinoma.
- The phase 3 POD1UM-303/InterAACT2 trial results, presented at the European Society for Medical Oncology Congress, found the median PFS in the combination group was 9.3 months compared to 7.4 months in the chemo only arm.
- Adding Zynyz, which targets PD-1, to platinum-based chemo led to a 37% reduction in the risk of progression or death.
- Overall response rate and duration of response, secondary endpoints, both showed greater improvement in the combination group versus the chemo only group: ORR of 56% vs. 44%; DOR of 14 months vs. 7 months.
Incyte Zynyz improves progression-free survival in anal most cancers (NASDAQ:INCY) | Invesloan.com
Updated: